Nisa Investment Advisors
AMPH icon

Nisa Investment Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Nisa Investment Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.07K Sell
361
-259
-42% -$6.34K ﹤0.01% 2356
2025
Q4 		$16.6K Sell
620
-9
-1% -$232 ﹤0.01% 2013
2025
Q3 		$16.8K Buy
629
+255
+68% +$6.58K ﹤0.01% 2076
2025
Q2 		$8.59K Sell
374
-850
-69% -$21.1K ﹤0.01% 2327
2025
Q1 		$35.5K Buy
1,224
+451
+58% +$14.4K ﹤0.01% 1690
2024
Q4 		$28.7K Buy
773
+53
+7% +$2.42K ﹤0.01% 1824
2024
Q3 		$34.9K Sell
720
-434
-38% -$19K ﹤0.01% 1738
2024
Q2 		$46.2K Buy
1,154
+1
+0.1% +$41 ﹤0.01% 1694
2024
Q1 		$50.6K Sell
1,153
-1,277
-53% -$66K ﹤0.01% 1650
2023
Q4 		$150K Buy
2,430
+1,300
+115% +$68.3K ﹤0.01% 1340
2023
Q3 		$52K Hold
1,130
– – ﹤0.01% 1716
2023
Q2 		$64.9K Hold
1,130
– – ﹤0.01% 1654
2023
Q1 		$42K Hold
1,130
– – ﹤0.01% 1767
2022
Q4 		$32K Hold
1,130
– – ﹤0.01% 1906
2022
Q3 		$35K Sell
1,130
-1,420
-56% -$46.4K ﹤0.01% 1870
2022
Q2 		$89K Buy
2,550
+460
+22% +$16.4K ﹤0.01% 1541
2022
Q1 		$75K Sell
2,090
-24,395
-92% -$692K ﹤0.01% 1720
2021
Q4 		$612K Sell
26,485
-62
-0.2% -$1.27K ﹤0.01% 967
2021
Q3 		$505 Sell
26,547
-5,717
-18% -$112K ﹤0.01% 1117
2021
Q2 		$650 Sell
32,264
-2,700
-8% -$50.9K ﹤0.01% 1070
2021
Q1 		$641 Hold
34,964
– – ﹤0.01% 1100
2020
Q4 		$703K Buy
34,964
+17,542
+101% +$341K ﹤0.01% 1061
2020
Q3 		$327K Sell
17,422
-17,329
-50% -$349K ﹤0.01% 1170
2020
Q2 		$781K Buy
34,751
+6,798
+24% +$125K 0.01% 869
2020
Q1 		$415K Hold
27,953
– – ﹤0.01% 981
2019
Q4 		$539K Buy
27,953
+5,423
+24% +$104K ﹤0.01% 1069
2019
Q3 		$447K Sell
22,530
-15,711
-41% -$327K ﹤0.01% 1129
2019
Q2 		$807K Hold
38,241
– – 0.01% 919
2019
Q1 		$781K Buy
38,241
+26,771
+233% +$600K 0.01% 920
2018
Q4 		$228K Hold
11,470
– – ﹤0.01% 1203
2018
Q3 		$221K Buy
+11,470
New +$204K ﹤0.01% 1290

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Nisa Investment Advisors's AMPH Position: Q1 2026 in Review

Nisa Investment Advisors reduced its Amphastar Pharmaceuticals (AMPH) stake by 42% in Q1 2026, selling an estimated $6.34K and leaving 361 shares worth $7.07K. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

Nisa Investment Advisors first reported a position in AMPH in Q3 2018 and has held it in 31 quarters since. The position peaked at $807K in Q2 2019. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Nisa Investment Advisors held 361 shares of Amphastar Pharmaceuticals worth $7.07K as of Q1 2026.
  • Nisa Investment Advisors sold 259 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $6.34K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2356 holding.
  • Nisa Investment Advisors first reported a position in Amphastar Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Nisa Investment Advisors's Amphastar Pharmaceuticals position peaked at $807K in Q2 2019.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.